1
Example of Assay Validation and Study ©2012 Carna Biosciences, Inc. ©2012 Cell Assay Innovations, LLC ClariCELL™ BMX Kinase Assay Service 4-Step Assay Validation BMX Expression in Cells BMX Autophosphorylation in Cells Quantification of Phosphorylation ELISA Activity Reference Inhibitor Data Figure 1: Wild type (WT) or kinase dead (K445M) BMX was expressed transiently in 293 cells. Following cell lysis, an IP Western was performed with appropriate antibodies to capture and detect total BMX protein. Figure 2: Wild type (WT) or kinase dead (K445M) BMX was expressed transiently in 293 cells. Following cell lysis, an IP Western was performed with appropriate antibodies to capture and detect phospho-BMX protein. Figure 3: Wild type (WT) or kinase dead (K445M) BMX was expressed transiently in 293 cells. Following cell lysis, an ELISA was performed to quantify the extent of autophosphorylation of BMX. Figure 4: An autophosphorylation assay was performed in the presence of ibrutinib, a BMX inhibitor. % inhibition data were plotted to determine the IC 50. Description The ClariCELL™ BMX Kinase Assay quantifies autophosphorylation of human full-length BMX in human cells. The assay is useful to determine potencies of smallmolecule inhibitors against the specified kinase in the context of a cellular environment. Compound testing services are available utilizing the assay. Overview Human Embryonic Kidney (HEK 293) cells transiently expressing sequence verified human full-length BMX are exposed to test compound or control, then lysed to release cellular proteins. BMX is captured onto an assay plate, and the extent of autophosphorylation is quantified by ELISA using an antibody specific for the phosphory- lation event. Cells expressing kinase deficient BMX [K445M] are also utilized as controls to calculate the % inhibition of test compounds. To learn more, please contact TEL:078-302-7091 / FAX:078-302-7086 E-mail:[email protected] Carna Biosciences, Inc. BMA 3F, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047 JAPAN

ClariCELL™ BMX Kinase Assay Service - CarnaBio · ClariCELL™ BMX Kinase Assay Service 4-Step Assay Validation BMX Expression in Cells BMX Autophosphorylation in Cells Quantification

  • Upload
    others

  • View
    8

  • Download
    0

Embed Size (px)

Citation preview

Page 1: ClariCELL™ BMX Kinase Assay Service - CarnaBio · ClariCELL™ BMX Kinase Assay Service 4-Step Assay Validation BMX Expression in Cells BMX Autophosphorylation in Cells Quantification

Example of Assay Validation and Study

©2012 Carna Biosciences, Inc.

©2012 Cell Assay Innovations, LLC

ClariCELL™ BMX Kinase Assay Service4-Step Assay Validation

BMX Expression in Cells BMX Autophosphorylation in Cells

Quantification of Phosphorylation

ELISA Activity

Reference Inhibitor Data

Figure 1: Wild type (WT) or kinase dead (K445M) BMX was expressed transiently in 293 cells. Following cell lysis, an IP Western was performed with appropriate antibodies to capture and detect total BMX protein.

Figure 2: Wild type (WT) or kinase dead (K445M) BMX was expressed transiently in 293 cells.Following cell lysis, an IP Western was performed with appropriate antibodies to capture and detect phospho-BMX protein.

Figure 3: Wild type (WT) or kinase dead (K445M) BMX was expressed transiently in 293 cells. Following cell lysis, an ELISA was performed to quantify the extent of autophosphorylation of BMX.

F igure 4: An autophosphorylation assay was per formed in the presence of ibrutinib, a BMX inhibitor. % inhibition data were plotted to determine the IC50.

DescriptionThe ClariCELL™ BMX Kinase Assay quantifies autophosphorylation of human full-length BMX in human cells. The assay is useful to determine potencies of smallmolecule inhibitors against the specified kinase in the context of a cellular environment. Compound testing services are available utilizing the assay.

OverviewHuman Embryonic Kidney (HEK 293) cells transiently expressing sequence verified human full-length BMX are exposed to test compound or control, then lysed to release cellular proteins. BMX is captured onto an assay plate, and the extent of autophosphorylation is quantified by ELISA using an antibody specific for the phosphory- lation event. Cells expressing kinase deficient BMX [K445M] are also utilized as controls to calculate the % inhibition of test compounds.

To learn more, please contact

TEL: 078-302-7091 / FAX: 078-302-7086E-mail: [email protected]

Carna Biosciences, Inc. BMA 3F, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047 JAPAN